Etanercept (full-dose) (DrugBank: Etanercept)
15 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
15 | Inclusion body myositis | 0 |
28 | Systemic amyloidosis | 0 |
35 | Pemphigus | 0 |
38 | Stevens-Johnson syndrome | 0 |
39 | Toxic epidermal necrolysis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
50 | Dermatomyositis | 0 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
60 | Aplastic anemia | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
228 | Bronchiolitis obliterans | 0 |
271 | Ankylosing spondylitis | 1 |
285 | Fanconi anemia | 0 |
298 | Hereditary pancreatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02638896 (ClinicalTrials.gov) | January 2016 | 20/12/2015 | Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis | Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: etanercept (Half-Dose);Drug: etanercept (Full-Dose);Drug: Sulfasalazine;Drug: Celecoxib | Zhixiang Huang | NULL | Not yet recruiting | 18 Years | 45 Years | Both | 100 | Phase 4 | NULL |